pravastatin has been researched along with benzyloxycarbonylleucyl-leucyl-leucine aldehyde in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Gao, F; Gui, YZ; Ma, YL; Wang, SM; Wang, XB; Wang, YP; Yan, H | 1 |
2 other study(ies) available for pravastatin and benzyloxycarbonylleucyl-leucyl-leucine aldehyde
| Article | Year |
|---|---|
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
MG132, a proteasome inhibitor, enhances LDL uptake in HepG2 cells in vitro by regulating LDLR and PCSK9 expression.
Topics: Anticholesteremic Agents; Gene Expression Regulation; Hep G2 Cells; Humans; Leupeptins; Lipoproteins, LDL; Liver; Pravastatin; Proprotein Convertase 9; Proprotein Convertases; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Kinase C; Real-Time Polymerase Chain Reaction; Receptors, LDL; Serine Endopeptidases | 2014 |